Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine in HCV Non-Responders
NCT00122629Phase 3Terminated
- Sponsor
- ANRS
- Start
- Oct 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amantadine in hepatitis C (HCV) (2 arms), sponsored by ANRS. Primary endpoint: Sustained Virological Response at 72 weeks. Started Oct 2000; status: terminated.
02
Drugs
amantadine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00122629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122629.